NSN's Q3 Revenue Up 36.6% YoY... "Aiming for Profitability Within the Year"

[Asia Economy Reporter Jang Hyowon] NSN announced on the 15th that its third-quarter performance this year improved across the board compared to the same period last year.

In the third quarter of this year, on a separate basis, sales amounted to 5.6 billion KRW, a 36.6% increase from 4.1 billion KRW in the same period last year. Although operating loss (-990 million KRW) and net loss (-1.14 billion KRW) were recorded, the company significantly reduced the deficit during the same period, successfully strengthening profitability.

In particular, external growth is accelerating. Sales have increased for three consecutive quarters this year. Third-quarter sales rose approximately 153% compared to the second quarter.

Since this year, NSN has actively embarked on restructuring its business portfolio, including promoting new businesses. It is focusing on improving its structure by reorganizing its business portfolio centered on high-profit businesses to achieve external growth and strengthen profitability.

NSN is pursuing future growth engines such as supplying PCR diagnostic devices and diagnostic kits, as well as ESG green industry distribution. Through its affiliate Seba Biotech, it is also accelerating its cannabis business and microbiome-based diagnostic solution business.

An NSN official stated, "With the promotion of new businesses this year, performance has steadily improved, and external growth and financial structure improvement are ongoing. We expect the distribution business segment’s performance to increase further due to year-end demand in the fourth quarter, and we aim to turn profitable this year."

This content was produced with the assistance of AI translation services.